Cargando…

Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib have shown promising efficacy and tolerability in patients with advanced NSCLC. Identifying subgroups of patients who benefit from EGFR-TKI treatment may help achieve better treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahriari, Saeedeh, Seifi, Sharareh, Khodakarim, Nastaran, Ramim, Tayeb, Dashtpeima, Alireza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iran University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448506/ https://www.ncbi.nlm.nih.gov/pubmed/36128277 http://dx.doi.org/10.47176/mjiri.36.31

Ejemplares similares

Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2015)

Relationship between weight gain and survival rate in patients with metastatic lung cancer
por: Fardad, Farshid, et al.
Publicado: (2021)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma
por: Tie, Xiaowei, et al.
Publicado: (2022)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
por: Amdahl, Jordan, et al.
Publicado: (2016)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma
por: Li, Wanwan, et al.
Publicado: (2019)

Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma
por: Liu, Xi, et al.
Publicado: (2018)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Nemeth, Zsuzsanna, et al.
Publicado: (2020)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Nomogram to predict overall survival and disease-specific survival with appendiceal mucinous adenocarcinoma
por: Yan, Qian, et al.
Publicado: (2019)

Predictive Model for Overall Survival and Cancer-Specific Survival in Patients with Esophageal Adenocarcinoma
por: Huang, He, et al.
Publicado: (2021)

Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection
por: Guan, Shasha, et al.
Publicado: (2019)

Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma
por: Lacedonia, Donato, et al.
Publicado: (2021)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2022)

Nomogram to Predict the Overall Survival of Colorectal Cancer Patients: A Multicenter National Study
por: Borumandnia, Nasrin, et al.
Publicado: (2021)

Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience
por: Barua, Sasanka Kumar, et al.
Publicado: (2019)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival
por: Botrus, Gehan, et al.
Publicado: (2022)

Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma
por: He, Chenglu, et al.
Publicado: (2021)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021)

Effectiveness of Plasmapheresis Treatment in the Treatment of Patients with COVID-19 Disease
por: Khodakarim, Nastaran, et al.
Publicado: (2022)

Metastatic colorectal cancer-prolonging overall survival with targeted therapies
por: Dattatreya, Satya
Publicado: (2013)

Role of Metastasectomy on Overall Survival of Patients with Metastatic Gastric Cancer
por: Yang, Seung Wook, et al.
Publicado: (2013)

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma
por: Shoushtari, A. N., et al.
Publicado: (2016)

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer
por: Goldstein, David, et al.
Publicado: (2020)

Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer
por: Xiao, Yuanyuan, et al.
Publicado: (2019)

Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Garattini, Silvio Ken, et al.
Publicado: (2021)

High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma
por: Zhou, Shijie, et al.
Publicado: (2017)

Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients
por: Tejerizo-García, Álvaro, et al.
Publicado: (2013)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kbaogao9baaqfsi3k1gucvatgr